Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. more
Time Frame | MDGL | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.29% | -2.12% | -3% |
1-Month Return | -2.73% | -3.42% | -0.73% |
3-Month Return | 32.1% | -11.13% | 2.87% |
6-Month Return | 15.18% | -5.74% | 7.17% |
1-Year Return | 39.54% | 3.97% | 25.31% |
3-Year Return | 286.03% | 1.05% | 28.38% |
5-Year Return | 244.51% | 34.37% | 81.89% |
10-Year Return | 221.63% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 21.86K | 37.32K | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":58.59,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 112.00K | 471.00K | 405.00K | 467.00K | 527.00K | [{"date":"2019-12-31","value":21.25,"profit":true},{"date":"2020-12-31","value":89.37,"profit":true},{"date":"2021-12-31","value":76.85,"profit":true},{"date":"2022-12-31","value":88.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (112.00K) | 21.86K | 273.00K | (467.00K) | (527.00K) | [{"date":"2019-12-31","value":-41.03,"profit":false},{"date":"2020-12-31","value":8.01,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-171.06,"profit":false},{"date":"2023-12-31","value":-193.04,"profit":false}] |
Gross Margin | - | 100.00% | 731.55% | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":13.67,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 94.97M | 206.67M | 242.48M | 293.57M | 380.50M | [{"date":"2019-12-31","value":24.96,"profit":true},{"date":"2020-12-31","value":54.32,"profit":true},{"date":"2021-12-31","value":63.73,"profit":true},{"date":"2022-12-31","value":77.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (94.97M) | (206.67M) | (242.48M) | (293.57M) | (380.50M) | [{"date":"2019-12-31","value":-9497200000,"profit":false},{"date":"2020-12-31","value":-20667300000,"profit":false},{"date":"2021-12-31","value":-24248200000,"profit":false},{"date":"2022-12-31","value":-29357100000,"profit":false},{"date":"2023-12-31","value":-38049600000,"profit":false}] |
Total Non-Operating Income/Expense | 22.05M | 8.76M | 999.00K | (3.56M) | 13.73M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.72,"profit":true},{"date":"2021-12-31","value":4.53,"profit":true},{"date":"2022-12-31","value":-16.14,"profit":false},{"date":"2023-12-31","value":62.28,"profit":true}] |
Pre-Tax Income | (83.95M) | (202.24M) | (241.85M) | (295.35M) | (373.63M) | [{"date":"2019-12-31","value":-8394800000,"profit":false},{"date":"2020-12-31","value":-20224400000,"profit":false},{"date":"2021-12-31","value":-24184600000,"profit":false},{"date":"2022-12-31","value":-29535000000,"profit":false},{"date":"2023-12-31","value":-37363000000,"profit":false}] |
Income Taxes | (11.14M) | (4.80M) | (768.00K) | 3.96M | - | [{"date":"2019-12-31","value":-280.93,"profit":false},{"date":"2020-12-31","value":-121.09,"profit":false},{"date":"2021-12-31","value":-19.37,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (72.81M) | (197.44M) | (241.08M) | (299.31M) | - | [{"date":"2019-12-31","value":-7281200000,"profit":false},{"date":"2020-12-31","value":-19744400000,"profit":false},{"date":"2021-12-31","value":-24107800000,"profit":false},{"date":"2022-12-31","value":-29931400000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (83.95M) | (202.34M) | (242.12M) | (295.35M) | (373.63M) | [{"date":"2019-12-31","value":-8394800000,"profit":false},{"date":"2020-12-31","value":-20234400000,"profit":false},{"date":"2021-12-31","value":-24211900000,"profit":false},{"date":"2022-12-31","value":-29535000000,"profit":false},{"date":"2023-12-31","value":-37363000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (72.81M) | (197.44M) | (241.08M) | (299.31M) | (373.63M) | [{"date":"2019-12-31","value":-7281200000,"profit":false},{"date":"2020-12-31","value":-19744400000,"profit":false},{"date":"2021-12-31","value":-24107800000,"profit":false},{"date":"2022-12-31","value":-29931400000,"profit":false},{"date":"2023-12-31","value":-37363000000,"profit":false}] |
EPS (Diluted) | (5.45) | (13.09) | (14.61) | (17.23) | (19.94) | [{"date":"2019-12-31","value":-545,"profit":false},{"date":"2020-12-31","value":-1309,"profit":false},{"date":"2021-12-31","value":-1461,"profit":false},{"date":"2022-12-31","value":-1723,"profit":false},{"date":"2023-12-31","value":-1994,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MDGL | |
---|---|
Cash Ratio | 5.62 |
Current Ratio | 5.98 |
Quick Ratio | 5.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MDGL | |
---|---|
ROA (LTM) | -52.25% |
ROE (LTM) | -129.76% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MDGL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MDGL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 87.58 |
P/B | 8.66 |
Price/FCF | NM |
EV/R | 76.21 |
EV/Ebitda | NM |
PEG | NM |
Madrigal Pharmaceuticals Inc (MDGL) share price today is $308.44
Yes, Indians can buy shares of Madrigal Pharmaceuticals Inc (MDGL) on Vested. To buy Madrigal Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MDGL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Madrigal Pharmaceuticals Inc (MDGL) via the Vested app. You can start investing in Madrigal Pharmaceuticals Inc (MDGL) with a minimum investment of $1.
You can invest in shares of Madrigal Pharmaceuticals Inc (MDGL) via Vested in three simple steps:
The 52-week high price of Madrigal Pharmaceuticals Inc (MDGL) is $368.29. The 52-week low price of Madrigal Pharmaceuticals Inc (MDGL) is $168.25.
The price-to-earnings (P/E) ratio of Madrigal Pharmaceuticals Inc (MDGL) is
The price-to-book (P/B) ratio of Madrigal Pharmaceuticals Inc (MDGL) is 8.66
The dividend yield of Madrigal Pharmaceuticals Inc (MDGL) is 0.00%
The market capitalization of Madrigal Pharmaceuticals Inc (MDGL) is $6.40B
The stock symbol (or ticker) of Madrigal Pharmaceuticals Inc is MDGL